CML Clinical Trials

4 recruiting

CML Trials at a Glance

20 actively recruiting trials for cml are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Houston, Paris, and Detroit. Lead sponsors running cml studies include University Hospital, Clermont-Ferrand, Australasian Leukaemia and Lymphoma Group (ALLG), and Augusta University.

Browse cml trials by phase

Treatments under study

About CML Clinical Trials

Looking for clinical trials for CML? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new CML trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about CML clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting
Phase 2

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

Chronic Myeloid Leukemia (CML)
Novartis Pharmaceuticals20 enrolled6 locationsNCT06514534
Recruiting
Phase 1Phase 2

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Neurofibromatosis 1Leukemia, Juvenile MyelomonocyticJMML+2 more
Therapeutic Advances in Childhood Leukemia Consortium58 enrolled19 locationsNCT05849662
Recruiting
Phase 1

UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

AMLMyelodysplastic SyndromesCML+3 more
University of Alabama at Birmingham50 enrolled1 locationNCT06047886
Recruiting
Phase 2

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

Leukemia, MyeloidChronic Myeloid Leukemia, Chronic PhaseLeukemia,Myeloid, Chronic+1 more
Augusta University100 enrolled7 locationsNCT05143840
Recruiting
Phase 2

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

LymphomaMyelofibrosisAML (Acute Myelogenous Leukemia)+8 more
Center for International Blood and Marrow Transplant Research358 enrolled13 locationsNCT06859424
Recruiting
Phase 1Phase 2

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+8 more
Ossium Health, Inc.12 enrolled9 locationsNCT05589896
Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

LymphomaAMLLeukemia+7 more
Children's Hospital Medical Center, Cincinnati30 enrolled5 locationsNCT06131801
Recruiting
Phase 1

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

B-cell Acute Lymphoblastic LeukemiaChronic Myeloid Leukemia (CML) in Lymphoid Blast CrisisPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
Marlise Luskin, MD40 enrolled4 locationsNCT03595917
Recruiting

Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology Network

Chronic Myeloid Leukemia (CML)
University of Milano Bicocca2,000 enrolled1 locationNCT07165535
Recruiting
Phase 2

PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

Chronic Myeloid LeukemiaChronic Myeloid Leukemia, Chronic PhaseCML, Chronic Phase+1 more
Gruppo Italiano Malattie EMatologiche dell'Adulto160 enrolled11 locationsNCT06409936
Recruiting
Phase 1

ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants

CML (Chronic Myelogenous Leukemia)Chronic Phase CML
Enliven Therapeutics21 enrolled4 locationsNCT06787144
Recruiting
Phase 3

Study of Olverembatinib (HQP1351) in Patients With CP-CML

Chronic Myeloid LeukemiaCMLCML, Chronic Phase
Ascentage Pharma Group Inc.285 enrolled1 locationNCT06423911
Recruiting
Phase 1Phase 2

Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML

CML,Blast Phase
Institute of Hematology & Blood Diseases Hospital, China29 enrolled1 locationNCT06757855
Recruiting
Phase 2

TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

Chronic Myeloid LeukemiaAccelerated Phase CML
Shenzhen TargetRx Co., Ltd.40 enrolled1 locationNCT06453902
Recruiting
Phase 3

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Chronic Myeloid Leukemia, Chronic PhaseCML, Chronic PhaseCML, Refractory+1 more
Il-Yang Pharm. Co., Ltd.173 enrolled18 locationsNCT03459534
Recruiting
Not Applicable

EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors

Chronic Myeloid Leukemia (CML)Chronic Phase
University Hospital, Clermont-Ferrand160 enrolled16 locationsNCT03481868
Recruiting

Chronic Myeloid Leukemia (CML) Real-Life Database

Chronic Myeloid Leukemia (CML)
University Hospital, Clermont-Ferrand3,500 enrolled14 locationsNCT05963061
Recruiting

Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction

Acute LeukemiaMDSMDS/MPN+1 more
Peking University People's Hospital300 enrolled1 locationNCT06211166
Recruiting
Phase 2

CML14 (ASCENDANCE) - A study to assess efficacy of combination therapy with asciminib plus low dose dasatinib in newly diagnosed chronic phase Chronic Myeloid Leukaemia (CML) with high risk genetics

Chronic Myeloid Leukaemia (CML)
Australasian Leukaemia and Lymphoma Group (ALLG)100 enrolled15 locationsACTRN12623001338651
Recruiting
Phase 1

A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

CML, Chronic PhaseCML, Accelerated Phase
Jiangsu Hansoh Pharmaceutical Co., Ltd.108 enrolled1 locationNCT05367700